Nightingale Health teams up with Alamar Biosciences on 80,000-sample UK Biobank neurodegenerative disease study

Bitget2026/11/02 13:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nightingale Health and Alamar Biosciences launched a UK Biobank study targeting earlier detection, prevention and treatment of neurodegenerative diseases.
The study will measure hundreds of protein biomarkers in 80,000 blood samples using Alamar's NULISA platform at Nightingale's laboratories.
Completion is expected by the end of 2027, with funding from Alzheimer's Research UK, LifeArc and other partners.
The full dataset will be available to approved researchers worldwide through the UK Biobank Research Analysis Platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nightingale Health Oyj published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nightingale Health teams up with Alamar Biosciences on 80,000-sample UK Biobank neurodegenerative disease study

You may also like

Crypto prices